Ripple USD (RLUSD) held a market capitalization lead of about $74 million over PayPal USD (PYUSD) as of November 13, with RLUSD at approximately $2.702 billion and PYUSD at about $2.628 billion. The difference widened from an earlier November 12 reading where RLUSD led by around $40 million. This shift is mainly due to a decrease in PYUSD's circulating supply by nearly 99.46 million tokens over 24 hours, while RLUSD's supply remained stable and even increased by about 70.63 million tokens over the past week. Both tokens are pegged to the US dollar, so changes in circulation directly affect their market capitalization rankings, which reflect token supply rather than transaction activity.
Ripple USD market cap lead is the story's subject, providing context for readers. For those following major cryptocurrencies on Pluang, 12 out of 50 rose and 37 fell today. Notable movers include BAL at Rp16.297 (+11.14%), ONE at Rp27 (-8.41%) with 40% sell and 60% buy order activity, and EOS at Rp12.649 (+8.13%). Data as of Nov 13, 2026 17:21 WIB.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
